Ladenburg Thalmann & Co. analyst Michael Higgins reiterated a Buy rating on Zynerba Pharmaceuticals (ZYNE) today and set a price target of $8.00. The company’s shares closed last Thursday at $3.49.
According to TipRanks.com, Higgins is a 4-star analyst with an average return of 10.8% and a 31.5% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Armata Pharmaceuticals, and Rhythm Pharmaceuticals.
Currently, the analyst consensus on Zynerba Pharmaceuticals is a Strong Buy with an average price target of $10.67.
See today’s analyst top recommended stocks >>
Based on Zynerba Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $9.05 million. In comparison, last year the company had a GAAP net loss of $1.95 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It engages in the development and commercialization of transdermal pharmaceutically-produced cannabinoid treatments for rare and near-rare neurological and psychiatric, or neuropsychiatric, disorders in patients with high unmet medical needs. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.
